S'abonner

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study - 14/09/15

Doi : 10.1016/j.jaad.2015.07.002 
Ian Landells, MD, FRCPC a, , Colleen Marano, PhD b, Ming-Chun Hsu, PhD b, Shu Li, PhD b, Yaowei Zhu, PhD b, Lawrence F. Eichenfield, MD c, Peter H. Hoeger, MD d, Alan Menter, MD e, Amy S. Paller, MS, MD f, Alain Taieb, MD g, Sandra Philipp, MD h, Philippe Szapary, MD, MSCE b, Bruce Randazzo, MD, PhD b, i
a Memorial University of Newfoundland, St. Johns, Newfoundland, Canada 
b Janssen Research & Development, LLC., Spring House, Pennsylvania 
c University of California, San Diego, California 
d University of Hamburg and Catholic Children's Hospital, Hamburg, Germany 
e Baylor University Medical Center and Texas A&M Health Science Center School of Medicine, Dallas, Texas 
f Northwestern University Feinberg School of Medicine, Chicago, Illinois 
g Bordeaux University Hospitals, University of Bordeaux, Bordeaux, France 
h Department of Dermatology and Allergy, Charité Universitätsmedizin Berlin, Germany 
i Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 

Reprint requests: Ian Landells, MD, FRCPC, Clinical Associate Professor, Memorial University of Newfoundland, Medical Director Dermatology, Nexus Clinical Research, 102-120 Stavanger Drive, St. John's, NL, A1B 2P1, Canada.

Abstract

Background

Safe and effective therapies are needed for pediatric patients with psoriasis.

Objective

The purpose of this study was to evaluate ustekinumab in patients age 12 to 17 years who had moderate-to-severe psoriasis.

Methods

Patients (n = 110) were randomly assigned to ustekinumab standard dosing (SD; 0.75 mg/kg [≤60 kg], 45 mg [>60-≤100 kg], and 90 mg [>100 kg]) or half-standard dosing (HSD; 0.375 mg/kg [≤60 kg], 22.5 mg [>60-≤100 kg], and 45 mg [>100 kg]) at weeks 0 and 4 and every 12 weeks or placebo at weeks 0 and 4 with crossover to ustekinumab SD or HSD at week 12. Clinical assessments included the proportion of patients achieving a Physician's Global Assessment of cleared/minimal (PGA 0/1), at least 75% improvement in Psoriasis Area and Severity Index (PASI 75), and at least 90% in PASI (PASI 90). Adverse events (AEs) were monitored through week 60.

Results

At week 12, 67.6% and 69.4% of patients receiving ustekinumab HSD and SD, respectively, achieved PGA 0/1 versus 5.4% for placebo (P < .001). Significantly greater proportions receiving ustekinumab achieved PASI 75 (HSD, 78.4%; SD, 80.6%; placebo, 10.8%) or PASI 90 (HSD, 54.1%; SD, 61.1%; placebo, 5.4%) at week 12 (P < .001). Through week 12, 56.8% of placebo patients, 51.4% of HSD patients, and 44.4% of SD patients reported at least one AE; through week 60, 81.8% reported AEs.

Limitations

The study was small relative to adult trials.

Conclusions

In this patient population (12–17 years), the standard ustekinumab dose provided response comparable to that in adults with no unexpected AEs through 1 year.

Le texte complet de cet article est disponible en PDF.

Key words : adolescent, biologic, children, pediatric, psoriasis, systemic therapy, ustekinumab

Abbreviations used : AE, CDLQI, HRQoL, HSD, PASI, PASI 75, PASI 90, PGA, PGA 0/1, SAE, SD


Plan


 Funding sources: This study (clnicaltrials.gov: NCT01090427) was sponsored by Janssen Research & Development, LLC.
 Conflicts of interest: Dr Landells has served as a consultant to AbbVie, Allergan, Amgen, Astellas, Basilea, Celgene, Dermik, Galderma, GlaxoSmithKline, Graceway, Janssen, L'Oreal, Leo, Merck/Schering-Plough, Roche, Stiefel, Valeant, and Wyeth; has received research grants from AbbVie, Amgen, and Janssen; has served as a trial investigator for AbbVie, Allergan, Amgen, Astellas, Basilea, Galderma, GlaxoSmithKline, Janssen, Leo, Merck/Schering-Plough, Pfizer, Roche, Stiefel, and Wyeth; has received honoraria from AbbVie, Amgen, Astellas, Graceway, Janssen, Merck/Schering-Plough, Steifel, and Wyeth; and has served as a speaker for AbbVie, Allergan, Amgen, Merck/Schering-Plough, Janssen, Roche, Valeant, and Wyeth. Dr Eichenfield has served as a consultant for Janssen and Leo; has served as a trial investigator for Galderma and Leo; and has served on a safety monitoring board for Amgen. Dr Hoeger has served as a consultant for Janssen and as a speaker for Allmirall, Galderma, and Pierre Fabre. Dr Menter has served as a consultant for AbbVie, Allergan, Amgen, Convoy Therapeutics, Eli Lilly, Janssen, Leo, Maruho, Novartis, Pfizer, Syntrix, Wyeth, and XenoPort; has served as a trial investigator for AbbVie, Allergan, Amgen, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Therapeutics, Eli Lilly, Genentech, Janssen, Leo, Maruho, Merck, Novartis, Pfizer, Syntrix, and Wyeth; and has served as a speaker for AbbVie, Amgen, Janssen, Leo, and Wyeth. Dr Paller has served as a consultant for AbbVie, Anacor, and Janssen and as an investigator for Abbvie, Amgen, and Anacor. Dr Taieb has served as a consultant for Janssen. Dr Philipp has served as a consultant Biogen Idec, Eli Lilly, and Pfizer; has received research support from Biogen Idec and Pfizer; has served as an investigator for AbbVie, Almirall, Amgen, Biogen Idec, Boehringer-Ingelheim, Celgene, Dermipsor Biomed LTD, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Leo, Maruho, MSD, Novartis, Pfizer, UCB Pharma, and VBL Therapeutics; has served as a speaker for Almirall, Amgen, Biogen Idec, Leo, Novartis, and Pfizer; and has served on an advisory board for AbbVie and Novartis. Drs Marano, Hsu, Li, Zhu, Szapary, and Randazzo are employees of the study sponsor and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC is a subsidiary.


© 2015  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 73 - N° 4

P. 594-603 - octobre 2015 Retour au numéro
Article précédent Article précédent
  • Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States
  • Caroline P. Schaefer, Joseph C. Cappelleri, Rebecca Cheng, Jason C. Cole, Scott Guenthner, Joseph Fowler, Sandy Johnson, Carla Mamolo
| Article suivant Article suivant
  • Rosacea is associated with chronic systemic diseases in a skin severity–dependent manner: Results of a case-control study
  • Barbara M. Rainer, Alexander H. Fischer, Dimitre Luz Felipe da Silva, Sewon Kang, Anna L. Chien

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.